Resonance Health is an Australian healthcare company specialising in the development and delivery of non-invasive medical imaging software and services. Our products are used by clinicians in the diagnosis and management of human diseases and by pharmaceutical companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high quality quantitative measurements essential in the management of particular diseases.
Resonance Health’s dedication to scientific rigour in the development and implementation of its analysis services has enabled it to achieve regulatory clearances in the US, Europe and Australia. This extends to a philosophy of quality management in all aspects of our operations. Resonance Health proudly carries ISO 13485 certification.
Resonance Health has demonstrated our expertise in liver imaging technologies with FerriScan. FerriScan has been available for over ten years and is globally recognised as the gold standard in the measurement of liver iron overload. FerriScan is used in over 30 countries worldwide, is quality assured and has regulatory clearance in the United States, Europe and Australia. It is the first such test to have achieved international regulatory approvals.
Measurement of liver iron concentration is critical in the management of patients with potentially fatal iron overload conditions. FerriScan is also available as a dual service with a Cardiac T2* measurement to enable better-informed decisions on the management of patients at risk of iron-induced organ damage.
HepaFat-Scan is currently undergoing a launch-to-market for the quantitative measurement of liver fat; following recent regulatory clearance in the US, Europe and Australia. HepaFat-Scan is now available for clinical use and for clinical trials requiring liver fat assessment.
Approximately thirty percent of the US population has fatty liver disease which is now the most common cause of liver disease in the western world. Other imaging techniques for diagnosing fatty liver, such as ultrasound, do not provide a quantitative measurement of the liver fat content to enable changes to be measured over time. Liver biopsy is the current gold standard for the diagnosis and measurement of fatty liver disease and HepaFat-Scan now provides a non-invasive alternative for patients.
Our ISO certified products are chosen by pharmaceutical companies for consistently accurate quantitative measurements required to assess the efficacy of their investigational products. Resonance Health offers Imaging Core Laboratory and Support Services for clinical trials including clinical measurement and project and data management services such as reporting, administration and support.
Resonance Health continues to perform research and development on existing and potential new products. Current research is focussed on the development of a quantitative MRI measurement of liver fibrosis, which is demonstrating promising results.